San Carlos, CA, August 02, 2012 --(PR.com
)-- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a mechanistic systems pharmacology workshop at ICSB-2012 - the 13th International Conference on Systems Biology in Toronto, Canada on August 19th, 2012. Dr. Christina Friedrich will be presenting the workshop entitled "Using Mechanistic Systems Pharmacology Modeling for Insight and Decision Support." The workshop is designed for professionals in drug discovery and development that want to gain a better understanding of how mechanistic systems pharmacology modeling, such as Rosa’s innovative PhysioPD™ approach, can improve scientific insight and enhance program decisions throughout the discovery and development pipeline. The workshop will cover key concepts in applying mechanistic systems pharmacology modeling to drug discovery and development. It will focus on Rosa’s Model Qualification Method, which sets out concrete criteria for ensuring and testing the quality of such models. Participants will work through a real-life case study that incorporates classical pharmacology, physiology, and mechanistic modeling into a systems pharmacology model. Concepts will be illustrated through the use of interactive exercises and demonstrations. The discussion will clearly delineate the similarities and differences between PK/PD modeling and mechanistic systems pharmacology modeling and describe how the approaches can be used in concert to improve scientific insight and guide drug development decisions. For more information about the workshop please see http://icsb2012toronto.com/information.php.
“The systematic approach to model building and qualification exemplified in the Rosa Model Qualification Method (MQM) sets a standard that is rapidly being adopted within the community, including many of our customers. The development of the MQM grew out of decades of experience in physiological mechanistic modeling and communicating modeling results to drug development decision makers. We look forward to sharing our ideas with the workshop participants,” said Dr. Friedrich, Chief Engineer, Rosa.
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.